No heart risks from Novartis’ Parkinson’s drug

Good news for drug manufacturing company Norvatis as U.S. health regulators
said on Monday that they found
no evidence of increased
cardiovascular risks related to
Novartis AG's treatment, Stalevo,
for Parkinson's disease.

Norvatis are the manufacturer of the drug Stalevo which is used for
treating Parkinson's disease. The story would have been different if
the FDA have discovered that their drug linked to any cardiovascular
disease.

Comments

Popular posts from this blog

Pfizer and Merck KGaA suffered another setback with immuno-oncology med Bavencio

Foods that help fight cancer

The U.S. Food and Drug Administration granted approval for expanded use of Imfinzi to treat non-small cell lung cancer (NSCLC) patients